Adil Javed
Neurology · Chicago, ILNPI 1932142833
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $363,147 of the $584,489 with a category attached, or 62.1%. It is spread thinly across 20 manufacturers, the largest accounting for just 19.6%. Reporting peaked in 2019 at $197,068 and has fallen 83.7% since, to $32,037 in 2025. Among neurology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 659 payments — averaging $886.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$115K
- Sanofi$82K
- Genentech USA, Inc.$79K
- Bristol Myers Squibb$70K
- Novartis$52K
- TG Therapeutics, Inc.$44K
- plus $142K from 14 others
Across 89 payments — averaging $9215.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$217K
- Chugai Pharmaceutical Co., Ltd.$160K
- Mallinckrodt Enterprises LLC$136K
- Genentech, Inc.$132K
- AstraZeneca$116K
- Hoffmann-la Roche Limited$42K
- plus $17K from 2 others
What the payments were for
- Consulting fees$172,81230%
- Speaking & faculty fees$363,14762%
- Travel & lodging$24,9104%
- Food & beverage$23,3854%
- Education$2360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 98 | $114,812 |
| Sanofi | 76 | $82,252 |
| Genentech USA, Inc. | 58 | $79,256 |
| Bristol Myers Squibb | 81 | $70,236 |
| Novartis | 68 | $52,384 |
| TG Therapeutics, Inc. | 55 | $43,708 |
| EMD Serono, Inc. | 109 | $41,208 |
| AstraZeneca | 35 | $33,950 |
| Amgen(2 entities) | 28 | $33,283 |
| E.r. Squibb & Sons, L.L.C. | 17 | $19,420 |
| Genentech, Inc. | 5 | $8,286 |
| Eisai CO., LTD. | 1 | $2,600 |
| Johnson & Johnson | 10 | $2,261 |
| AbbVie | 10 | $251 |
| Eisai Inc. | 2 | $178 |
| Grifols USA, LLC | 1 | $132 |
| Nobelpharma America, LLC | 1 | $118 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Springworks Therapeutics, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPOSIA$53,201
- OCREVUS$48,561
- BRIUMVI$40,092
- AUBAGIO$37,824
- Enspryng$33,309
- UPLIZNA$32,807
- TECFIDERA$30,648
- Vumerity$30,110
- Ozanimod$29,967
- Mavenclad$23,461
- TYSABRI$17,616
- MAYZENT$14,616
- LEMTRADA$12,453
- SOLIRIS$8,239
- ARZERRA$7,263
- KESIMPTA$7,034
- DISEASE STATE$6,791
- PLEGRIDY$6,688
- GILENYA$6,118
- Non-Covered Product$4,766
How this compares
$584,489 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnspryngSatralizumab-Mwge | 45 | $1,250,251 |
| AubagioTeriflunomide | 86 | $966,656 |
| Kesimpta PenOfatumumab | 51 | $505,399 |
| TecfideraDimethyl Fumarate | 31 | $292,139 |
| CopaxoneGlatiramer Acetate | 51 | $274,589 |
| BetaseronInterferon Beta-1b | 26 | $237,619 |
| Teriflunomide | 29 | $150,661 |
| RebifInterferon Beta-1a/Albumin | 12 | $123,621 |
| VumerityDiroximel Fumarate | 13 | $99,739 |
| Emgality PenGalcanezumab-Gnlm | 34 | $41,924 |
| Dalfampridine ErDalfampridine | 54 | $19,088 |
| Dimethyl Fumarate | 27 | $12,874 |
| Baclofen | 291 | $5,947 |
| Gabapentin | 303 | $5,384 |
| Modafinil | 81 | $4,935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Enspryng | $79,256 | $1,250,25145 claims |
| SanofiAubagio | $82,252 | $966,65686 claims |
| BiogenTecfidera, Vumerity | $114,812 | $391,87844 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone, Albuterol Sulfate | $21 | $275,93369 claims |
| EMD Serono, Inc.Rebif | $41,208 | $123,62112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.
Other neurology in Chicago
- Augusto MiravalleChicago$1.4M
- Danny BegaChicago$442K
- Michael SmithChicago$382K
- Dusan StefoskiChicago$294K
- Veronica CiprianiChicago$289K
- Thomas ShoemakerChicago$278K
- Bruce CohenChicago$276K
- Margaret ParkChicago$245K
- Leonard Verhagen MetmanChicago$245K
- Tatyana SimuniChicago$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.